Targeting cell cycle and apoptosis for the treatment of human malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Oncogenic transformation disrupts normal cell cycle progression and apoptosis regulation.
• Targeting cell cycle and apoptosis pathways is a key strategy in cancer treatment.
• Dysregulation of proteins like p53, bcl-2, AKT, and EGFR impacts apoptosis and proliferation.

Purpose of the Study:

• To review current strategies for modulating cell cycle and apoptosis in cancer therapy.
• To discuss the mechanisms of action for small molecule inhibitors targeting cell cycle kinases (CDKs) and apoptosis pathways.
• To highlight challenges and future directions in developing targeted cancer therapies.

Main Methods:

• Review of small molecule inhibitors targeting cell cycle (CDK) and apoptosis pathways.
• Discussion of protein targets including p53, bcl-2, AKT, ras, and EGFR.
• Exploration of novel technologies like genomics and proteomics for personalized medicine.

Main Results:

• Several small molecules targeting cell cycle and apoptosis have been recently approved or are in late-stage development.
• Modulation of CDKs via ATP-binding pocket inhibitors or altering inhibitor complexes is a viable approach.
• Targeting pro-apoptotic or pro-survival pathways offers therapeutic potential.

Conclusions:

• Targeting cell cycle and apoptosis pathways holds significant promise for cancer therapy.
• Challenges include achieving tumor-specific targeting and developing effective combination therapies.
• Genomics and proteomics will be crucial for tailoring combinatorial regimens to individual patients.